58 results about "Clotting factors" patented technology

Microneedle devices are provided for controlled sampling of biological fluids in a minimally-invasive, painless, and convenient manner. The microneedle devices permit in vivo sensing or withdrawal of biological fluids from the body, particularly from or through the skin or other tissue barriers, with minimal or no damage, pain, or irritation to the tissue. The microneedle device includes one or more microneedles, preferably in a three-dimensional array, a substrate to which the microneedles are connected, and at least one collection chamber and/or sensor in communication with the microneedles. Preferred embodiments further include a means for inducing biological fluid to be drawn through the microneedles and into the collection chamber for analysis. In a preferred embodiment, this induction is accomplished by use of a pressure gradient, which can be created for example by selectively increasing the interior volume of the collection chamber, which includes an elastic or movable portion engaged to a rigid base. Preferred biological fluids for withdrawal and/or sensing include blood, lymph, interstitial fluid, and intracellular fluid. Examples of analytes in the biological fluid to be measured include glucose, cholesterol, bilirubin, creatine, metabolic enzymes, hemoglobin, heparin, clotting factors, uric acid, carcinoembryonic antigen or other tumor antigens, reproductive hormones, oxygen, pH, alcohol, tobacco metabolites, and illegal drugs.

A compound represented by the following general formula (1), or a salt thereof has serine protease inhibiting activity, and particularly excellent inhibiting activity against clotting factor VIIa. This compound or a salt thereof is useful as therapeutic and/or prophylactic agents for diseases associated with thrombus formation.

[wherein R¹ represents hydrogen, R² represents optionally substituted phenyl, etc., R³ represents optionally substituted C6-10 aryl, etc.]

The invention provides an insoluble polysaccharide compound with a hemostatic function. The compound includes insoluble polysaccharide and a blood component. The blood component is whole blood or plasma, and the insoluble polysaccharide is macromolecular polysaccharide insoluble in whole blood or plasma. According to the invention, by mixing the blood component with the insoluble polysaccharide, the blood component undergoes clotting reaction evenly and dispersedly on the surface of the insoluble polysaccharide, so that clotting factors generated in the clotting process can be adsorbed by the insoluble polysaccharide surface, and high clotting activity can be maintained, thereby obtaining a composite hemostatic material with an excellent clotting effect. The preparation method of the insoluble polysaccharide compound provided by the invention is simple, and is convenient and safe to use, thus being widely applicable to trauma and surgical hemostasis. The insoluble polysaccharide compound can be combined with other medical materials and medical instruments so as to be prepared into band aids, infusion bands, self-adhesive dressings, tablets and capsule core materials, operation packages and first-aid packets, etc. At the same time, the adsorption performance and other characteristics of the insoluble polysaccharide compound are utilized to adsorb antibiotics, painkillers and the like thereinto, thus achieving better curative effect.

The invention discloses a recombined human coagulation factor FVII-Fc fusion protein as well as a preparation method and an application thereof. The fusion protein sequentially comprises human FVII, a flexible peptide junction and an IgG2Fc variant from an N terminal to a C terminal, wherein the Fv variant has no splitting property and shows tiny Fc-mediated adverse side effect. The fusion protein has the biological activity similar to or higher than that of the human FVII and greatly prolonged plasma half-life, thus the pharmacodynamics and the drug effect are improved.

The present disclosure provides nucleic acid molecules comprising a first inverted terminal repeat (ITR), a second ITR, and a genetic cassette encoding a target sequence. In some embodiments, the target sequence encodes a miRNA and/or a therapeutic protein. In certain embodiments, the therapeutic protein comprises a clotting factor, a growth factor, a hormone, a cytokine, an antibody, a fragment thereof, and a combination thereof. In some embodiments, the first ITR and/or the second ITR is an ITR of a non-adeno-associated virus (AAV). The present disclosure also provides methods of treating a metabolic disorder of the liver in a subject comprising administering to the subject the nucleic acid molecule or a polypeptide encoded thereby.

The invention provides preparation of a antibacterial hemostatic porous microsphere with good biocompatibility, nontoxicity and biodegradability. The sodium alginate/cellulose nanocrystalline porous microsphere is prepared by using an inverse emulsion method. The antibacterial hemostatic porous microsphere of sodium alginate and cellulose nanocrystalline has simple preparation method, available materials, and good safety coefficient. The sodium alginate/nanocrystalline cellulose loaded epsilon-polylysine porous microsphere prepared by the method of the invention is applied in wound hemostasis to quickly absorb blood, reduce blood flow and promote local aggregation of red blood cells, blood coagulation factors and platelets at a wound, thereby promoting hemostasis. In addition, the antibacterial hemostatic porous microsphere of the present invention can prevent wound infection and promote tissue healing due to antibacterial performance.

The present invention relates to the field of gastric cancer. More specifically, the present invention provides methods and compositions for diagnosing and treating gastric cancer. In a specific embodiment, a method for diagnosing gastric cancer or a likelihood thereof in a patient comprises the steps of (a) providing a sample from the patient; (b) measuring the methylation levels of one or more biomarkers in the sample collected from the patient; and (c) predicting gastric cancer in the patient if the biomarkers are hypermethylated. In a more specific embodiment, the one or more biomarkers comprises tight junction protein claudin-1 1 (CLD-N11), the transcription factor BarH-like homeobox (BARX1), basonuclin1 (BNC1), Coagulation factor C homolog (COCH), filamin C gamma (FLNC), cytoglobin B (CYGB), glutamine-fructose-6-phospahe-transaminase-2 (GFPT2), heat-shock-70 kDa protein-6 (HSPA6), snail homolog 1(SNAL1), skin calmodulin-related factor (SCARF), and tumor protein p53 binding protein 2 (TP53BP2).

The present invention provides a soluble phospholipid reagent and assays of clotting activity using the same. The methods of the invention can be used to carry out any clotting assay or other assay of clotting activity that traditionally relies on platelet membranes or synthetic membrane preparation by substituting therefor the soluble phospholipids of the invention. Assay compositions and kits comprising the soluble phospholipids of the invention are also provided.

The present invention relates generally to novel macrocycles of Formula (I) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein the variables A, B, C, D, L, M, W, Z1, Z2, Z3, Z4, R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 are as defined herein. These compounds are selective inhibitors of factor VIIa which can be used as medicaments.

The present invention includes composition and methods of using a lipid nanodisk or nanotube composition comprising a lipid composition of phosphatidylserine and galactosylceramide and a membrane-bound Factor VIII protein, a membrane-bound Factor IX protein, a membrane-bound Factor VIII-Factor IX protein complex, or a membrane-bound Factor V-Factor X protein complex in or about the lipid nanodisks or nanotubes.

Embodiments of the invention provides methods and devices which enable a quick, easy, and cost-effective test for detecting the presence of coagulation factor (CF) inhibitors and platelet (P) inhibitors within small volumes of patient-derived liquid samples. The inventive approach reduces the need for elaborate and time-consuming sample testing or larger quantities of a sample to be collected. The inventive approach overcomes further limitations by providing a detection method that is suitable for measuring antiplatelet drugs, as well as methods for detecting CF inhibitors which are not dependent on competition between CF inhibitors and chromogenic substrates and enzymatic cleaving, but instead relies on non-competitive configurations involving the use of sequential binding moieties with specificity toward CF/P inhibitors and subsequent complexes and/or competitive configurations involving the use of binding moieties that will compete for CF inhibitors against either modified CF inhibitors or other competing moieties.

The disclosed invention is a device and method of use for gauze utilized in the treatment of hemorrhage. In an embodiment the device combines clotting factor concentrator gauze and urea in order to slow hemorrhage and prevent hemorrhage induced coagulopathy. In an embodiment, the gauze is comprised of a first layer comprised of gauze and a second layer embedded with urea. The urea reacts spontaneously when it comes into contact with water, and undergoes an endothermic reaction. This endothermic reaction cools the smaller blood vessels exposed from soft tissue trauma, causing enhanced platelet activity as well as vasoconstriction to minimize the bleeding that occurs before and after the clotting cascade is activated over the entire wound surface.

Embodiments provide devices, preparations and methods for delivering therapeutic agents (TAs) such as clotting factors (CFs), e.g., Factor VIII (FVIII) including PEGylated and other forms of stabilized FVIII, within the GI tract. Many embodiments provide a swallowable device e.g., a capsule for delivering TAs into the intestinal wall (IW). Embodiments also provide TA preparations configured to be contained within the capsule, advanced from the capsule into the IW and/or surrounding tissue (ST) and degrade to release the TA into the bloodstream to produce a therapeutic effect (e.g., improved clotting). The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the IW or ST (e.g., the peritoneal cavity). Embodiments are particularly useful for delivery of CFs for treatment of clotting disorders (e.g., hemophilia) where such CFs are poorly absorbed and/or degraded within the GI tract.

The present invention provides an ex vivo method for aiding the diagnosis of Alzheimer's disease in a patient comprising: (i) determining the number of alleles of ApoE4 in the patient's genome; (ii) determining the combined expression level of at least three platelet proteins in a platelet sample from the patient; and (iii) comparing the resulting value of step (ii) to a control value, wherein the at least three platelet proteins include at least one isoform of alpha-tropomyosin containing exon 1a and at least two platelet proteins selected from monoamine oxidase-B, coagulation factor XIIIa, wild-type GSTO-1 or mutant GSTO-1, wherein a result higher than the control value is indicative of Alzheimer's disease.

The invention also provides a solid support comprising one or more ligands of at least one isoform of alpha-tropomyosin containing exon 1a, and one or more ligands of at least two platelet proteins selected from monoamine oxidase-B, coagulation factor XIIIa, wild-type GSTO-1 protein and/or mutant GSTO-1 protein immobilised thereon.